Welcome to our dedicated page for Checkpoint Therapeutics SEC filings (Ticker: CKPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Checkpoint Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Checkpoint Therapeutics's regulatory disclosures and financial reporting.
Checkpoint Therapeutics received a Schedule 13G/A filing from Beryl Capital and affiliated entities reporting they do not beneficially own any shares of the company's common stock. The filing shows 0 shares held and 0% of the class and explicitly states the reporting persons disclaim beneficial ownership except for any pecuniary interest.
The filing identifies the reporting parties as an investment adviser and related partnerships, confirms the position is reported as "5 percent or less of a class," and includes certifications that the securities were not acquired to influence control. Signatures from Beryl's COO and David A. Witkin are included.